title: Disease recurrence in paediatric renal transplantation.
abstract: Renal transplantation (Tx) is the treatment of choice for end-stage renal disease. The incidence of acute rejection after renal Tx has decreased because of improving early immunosuppression, but the risk of disease recurrence (DR) is becoming relatively high, with a greater prevalence in children than in adults, thereby increasing patient morbidity, graft loss (GL) and, sometimes, mortality rate. The current overall graft loss to DR is 7-8%, mainly due to primary glomerulonephritis (70-80%) and inherited metabolic diseases. The more typical presentation is a recurrence of the full disease, either with a high risk of GL (focal and segmental glomerulosclerosis 14-50% DR, 40-60% GL; atypical haemolytic uraemic syndrome 20-80% DR, 10-83% GL; membranoproliferative glomerulonephritis 30-100% DR, 17-61% GL; membranous nephropathy approximately 30% DR, approximately 50% GL; lipoprotein glomerulopathy approximately 100% DR and GL; primary hyperoxaluria type 1 80-100% DR and GL) or with a low risk of GL [immunoglobulin (Ig)A nephropathy 36-60% DR, 7-10% GL; systemic lupus erythematosus 0-30% DR, 0-5% GL; anti-neutrophilic cytoplasmic antibody (ANCA)-associated glomerulonephritis]. Recurrence may also occur with a delayed risk of GL, such as insulin-dependent diabetes mellitus, sickle cell disease, endemic nephropathy, and sarcoidosis. In other primary diseases, the post-Tx course may be complicated by specific events that are different from overt recurrence: proteinuria or cancer in some genetic forms of nephrotic syndrome, anti-glomerular basement membrane antibodies-associated glomerulonephritis (Alport syndrome, Goodpasture syndrome), and graft involvement as a consequence of lower urinary tract abnormality or human immunodeficiency virus (HIV) nephropathy. Some other post-Tx conditions may mimic recurrence, such as de novo membranous glomerulonephritis, IgA nephropathy, microangiopathy, or isolated specific deposits (cystinosis, Fabry disease). Adequate strategies should therefore be added to kidney Tx, such as donor selection, associated liver Tx, plasmatherapy, specific immunosuppression protocols. In such conditions, very few patients may be excluded from kidney Tx only because of a major risk of DR and repeated GL. In the near future the issue of DR after kidney Tx may benefit from alternatives to organ Tx, such as recombinant proteins, specific monoclonal antibodies, cell/gene therapy, and chaperone molecules.
authors.affiliation: Centre de référence des maladies rénales rares, Inserm U, Hôpital Femme Mère Enfant & Université de Lyon, Bron, France. pierre.cochat@chu-lyon.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Cochat
authors.forename: Sonia
authors.initials: S
authors.lastname: Fargue
authors.forename: Guillaume
authors.initials: G
authors.lastname: Mestrallet
authors.forename: Therese
authors.initials: T
authors.lastname: Jungraithmayr
authors.forename: Paulo
authors.initials: P
authors.lastname: Koch-Nogueira
authors.forename: Bruno
authors.initials: B
authors.lastname: Ranchin
authors.forename: Lothar Bernd
authors.initials: LB
authors.lastname: Zimmerhackl
mesh_terms: D002648:Child; D002675:Child, Preschool; D005921:Glomerulonephritis / Q000453:epidemiology / Q000209:etiology / Q000601:surgery; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000209:etiology / Q000601:surgery; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000209:etiology / Q000601:surgery; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000209:etiology / Q000601:surgery; D006084:Graft Rejection / Q000601:surgery; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000209:etiology / Q000601:surgery; D006801:Humans; D006960:Hyperoxaluria, Primary / Q000150:complications / Q000209:etiology / Q000601:surgery; D015994:Incidence; D007668:Kidney / Q000601:surgery; D007674:Kidney Diseases / Q000150:complications / Q000453:epidemiology / Q000209:etiology*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic; D012008:Recurrence; D012307:Risk Factors